Study testing mRNA vaccine for multiple sclerosis relapse prevention
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have been diagnosed with relapsing multiple sclerosis (MS) within the last 2 years, including a first attack or a finding on MRI without symptoms.
- You have a positive test for Epstein-Barr virus (EBV), a common virus linked to MS.
- You have been neurologically stable for at least 30 days before starting the study.
- If you can become pregnant, you must not be pregnant or breastfeeding and must use reliable birth control.
- You have not taken strong immune-suppressing drugs (like high-dose steroids) in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.